Review Article

Clinical Use of PPAR\(\gamma\) Ligands in Cancer

Jennifer L. Hatton and Lisa D. Yee

Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, OH 43210, USA

Correspondence should be addressed to Lisa D. Yee, lisa.yee@osumc.edu

Received 22 March 2008; Revised 11 August 2008; Accepted 29 September 2008

Recommended by Dipak Panigrahy

The role of PPAR\(\gamma\) in adipocyte differentiation has fueled intense interest in the function of this steroid nuclear receptor for regulation of malignant cell growth and differentiation. Given the antiproliferative and differentiating effects of PPAR\(\gamma\) ligands on liposarcoma cells, investigation of PPAR\(\gamma\) expression and ligand activation in other solid tumors such as breast, colon, and prostate cancers ensued. The anticancer effects of PPAR ligands in cell culture and rodent models of a multitude of tumor types suggest broad applicability of these agents to cancer therapy. This review focuses on the clinical use of PPAR ligands, specifically the thiazolidinediones, for the treatment and prevention of cancer.

1. INTRODUCTION

The peroxisome proliferator-activated receptor \(\gamma\) (PPAR\(\gamma\)) is a ligand-activated transcription factor in the superfamily of the steroid/thyroid nuclear hormone receptors, one of three PPAR isotypes (\(\alpha\), \(\beta/\delta\), and \(\gamma\)) [1–3]. PPARs share a highly conserved DNA-binding domain that matches with specific DNA sequences known as peroxisome proliferator response elements (PPREs), binding as a heterodimer with retinoid X receptor (RXR) to initiate transcription of target genes [4–6]. Highly expressed in adipose tissue, PPAR\(\gamma\) is best known for its important role in adipocyte differentiation [7–9].

PPARs were first shown to be activated by compounds inducing peroxisome proliferation [10, 11], then by a variety of polyunsaturated fatty acids (PUFAs) in the micromolar range [12]. PPAR\(\gamma\) has a more restricted list of activators compared to the other two isotypes, being more selective to PUFAs compared to other fatty acids [13, 14]. Fatty acid derivatives, such as 15-deoxy-\(\Delta\)12,14-PGJ\(_2\) (15d-PGJ\(_2\)) and 13- and 9-hydroxyoctadecadienoic acid (HODE), have also been identified as activators of PPAR\(\gamma\) [15–17]. Synthetic ligands for PPAR\(\gamma\) include the thiazolidinediones, a class of oral hypoglycemic drugs that reduce hyperglycemia and hyperinsulinemia in insulin-resistant states [18]. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen are also PPAR\(\gamma\) ligands, but exhibit much lower binding affinities in comparison to thiazolidinediones [19].

A wealth of preclinical data supports a role for PPAR\(\gamma\) ligand therapy in many different types of solid malignancies. Experimental studies of human cancer cells and PPAR\(\gamma\) have focused primarily on the \(\gamma\)-activating effects of thiazolidinediones, identifying PPAR\(\gamma\) agonists as negative regulators of cell growth and tumor progression. As a putative natural ligand for PPAR\(\gamma\), 15d-PGJ\(_2\) also appears to have anticancer effects. Treatment with PPAR\(\gamma\) ligands inhibits malignant cell proliferation, with evidence for cell cycle arrest and induction of apoptosis [20–25]. With the pivotal role of PPAR\(\gamma\) in adipocyte differentiation, PPAR\(\gamma\) ligands have been tested for differentiating effects on malignant cells. Changes consistent with induction of a more differentiated cancer cell phenotype were detected in several tumor model systems, including breast, colon, and liposarcoma [9, 26–30].

The anticancer effects of PPAR\(\gamma\) agonists may also be mediated in part via suppression of an angiogenic tumor phenotype or angiogenic, inflammatory tumor microenvironment. PPAR\(\gamma\) ligands appear to elicit antiangiogenic effects, via modulation of endothelial cell function and growth [31–35]. The anti-inflammatory actions of PPAR\(\gamma\) ligands [36–38], which are of relevance to the treatment of atherosclerosis and cardiovascular disease, may also prove important for the treatment and prevention of cancer given the association of chronic inflammation with increased cancer risk [39].
Approved by the Food and Drug Administration for treatment of type 2 diabetes mellitus, thiazolidinediones have been evaluated for use as investigational cancer therapies. The initial studies utilized troglitazone (Rezulin), which was the first thiazolidinedione in clinical use but ultimately withdrawn from the US market in 2000 because of instances of severe idiopathic liver disease [40]. Rosiglitazone (Avandia) and pioglitazone (Actos) were thereafter used without evidence of similar hepatotoxicity. The majority of clinical trials of thiazolidinediones have been conducted in advanced stages of disease. The following review examines the clinical trial experience to date with thiazolidinediones in cancer.

2. MONOTHERAPY

Searches of the PubMed and www.clinicaltrials.gov databases identified nine clinical trials testing the efficacy of thiazolidinediones as single agent therapy in cancer patients, with the majority conducted in subjects with advanced and/or metastatic stages of disease refractory to treatment. Troglitazone was the drug of choice for human studies initiated prior to 2000, replaced by rosiglitazone or pioglitazone in trials conducted after the withdrawal of troglitazone from clinical use because of rare instances of hepatotoxicity. Thiazolidinediones have been generally administered at the highest recommended dose for treatment of diabetes mellitus, or slightly higher as with troglitazone at 800 mg/day. Rather than mimic the generalized cytotoxicity of chemotherapeutic regimens, such doses might selectively target PPARγ-mediated effects such as cellular differentiation, growth inhibition, and induction of apoptosis.

2.1. Liposarcomas

As mesenchymal malignancies that arise from adipose tissue [41, 42], liposarcomas express PPARγ at levels comparable to normal adipose tissue [26]. PPARγ expression is a distinguishing feature of liposarcomas relative to other soft tissue sarcomas [43]. Treatment of primary cell strains derived from human liposarcomas (two well-differentiated liposarcomas and one intermediate grade myxoid/round cell liposarcoma) with PPARγ and/or RXR ligands induced morphologic and molecular changes consistent with adipocyte differentiation [26]. These in vitro findings led to consideration of thiazolidinediones for differentiation therapy of liposarcomas.

Demetri et al. conducted an open label phase II clinical trial to determine the effects of troglitazone (800 mg/day) on tumor differentiation in patients with advanced and/or metastatic liposarcoma [44]. In a report of three study subjects, tumor samples obtained after the six week intervention showed marked cytoplasmic lipid accumulation in comparison to pretreatment biopsies, as well as morphologic changes suggestive of mature adipocytes. The expression of markers of adipocyte differentiation such as adipin, aP2, and PPARγ by Northern analysis increased following treatment with troglitazone. Furthermore, cell proliferation as assessed by the percentage of liposarcoma cells with Ki67 immunostaining decreased by two- to fourfold with the study intervention. Three additional patients enrolled in the study also had post-treatment biopsies with histologic evidence of adipocyte differentiation and decreased cell proliferation. The histologic subtypes treated in this study ranged from intermediate to high grade, and the authors raise the possibility that differentiation may prove difficult to assess in more differentiated tumors. This small pilot trial of six subjects demonstrated a differentiating effect of short-term troglitazone therapy in advanced stage liposarcomas providing the rationale for further clinical evaluation of troglitazone and other PPARγ ligands in the management of liposarcomas.

A second phase II trial evaluated the effects of the thiazolidinedione rosiglitazone (8 mg administered as 4 mg twice daily) in nine patients with advanced, unresectable liposarcomas [45]. Analyses of tumor samples obtained at 0, 6, and 12 weeks did not reveal changes in histopathology or gene expression to support a differentiating effect. By quantitative RT-PCR, levels of adipin, fatty acid-binding protein (FABP), and PPARγ increased in only two of nine tumors although in a somewhat inconsistent fashion. In one of the patients with a dedifferentiated liposarcoma, expression of PPARγ increased at week 12, FABP at week 6 and adipin at weeks 6 and 12. However, disease progression had been detected in this patient at 10 weeks of treatment, such that the expression of differentiation markers did not correlate with clinical benefit. For the other subject, upregulation of adipin at week 12 was noted in a myxoid liposarcoma, and treatment continued until progression of disease at six months. Cell proliferation assessed by Ki67 immunostaining did not decrease significantly with the study intervention, although the low baseline levels of proliferation decreased further with rosiglitazone. Taken together the data fail to support a role for rosiglitazone in the treatment of liposarcoma at advanced stages.

The discrepant findings between the two phase II trials of thiazolidinedione therapy may relate to differences in the patient cohorts, tumors, and/or study agents. Whether methodological issues contributed to the differences is not clear. As surgery remains the mainstay of treatment for liposarcomas, with limited therapeutic options for unresectable, advanced disease, and investigation of PPARγ ligands for adjuvant therapy of liposarcoma or control of microscopic or minimal residual disease may still be warranted.

2.2. Colon cancer

Considerable in vitro evidence exists to support the differentiating and antiproliferative effects of PPARγ ligand therapy in colon cancer. PPARγ is highly expressed in human colon tumor specimens and cancer cell lines [27, 46]. In addition to growth inhibition, treatment of colon cancer cells with PPARγ ligands promotes tumor cell differentiation as assessed by increased cytoplasmic to nuclear ratio and higher levels of differentiation markers such as carcinoembryonic antigen (CEA), villin, intestinal alkaline phosphatase, GOb-4, and keratin 20 [27, 29, 47]. Although in vitro and in vivo studies demonstrate a role for PPARγ in modulating
growth and differentiation of human colon cancer cell lines [27], thiazolidinedione treatment with rosiglitazone (BRL49653) or troglitazone stimulated rather than inhibited the development of colon tumors in APC\textsuperscript{min/+} mice [48, 49]. The loss of adenomatous polyposis coli (APC) tumor suppressor gene function, which leads to accumulation of β-catenin and enhanced Wnt pathway signaling, may account for the contradictory findings of enhanced tumorigenesis in this genetic versus xenograft model of colon cancer [50]. Interestingly, treatment with pioglitazone over a wide range of doses suppressed intestinal tumor formation and hyperlipidemia in APC deficient mice (APC\textsuperscript{min/+} and Apc1309) [51, 52]. Whether the use of different thiazolidinediones or experimental conditions led to the discrepant findings is unclear.

Loss of function mutations in \textit{PPARG} in colon cancer may also account for variability in response to PPAR\textgamma therapy. Four unique mutations of PPAR\textgamma were identified in 55 sporadic colon cancers in exons 3 or 5; one yielding a truncated protein with loss of the ligand binding domain (c.472delA) and three causing defects in the binding of synthetic or natural ligands (Q286P, K319X, and R288H) [53]. A point mutation in exon 6, K422Q, was detected in four human colon cancer cell lines that were resistant to the antiproliferative and differentiating effects of PPAR\textgamma ligands [54]. However, K422Q may have limited clinical relevance, as a study of 170 primary human colorectal cancers and 12 liver metastases failed to detect the presence of K422Q mutations [55].

A phase II trial evaluated troglitazone therapy (800 mg/day as a single dose) in 25 colon cancer patients with lung and/or liver metastases [56]. Although well-tolerated, troglitazone did not elicit objective tumor responses. All patients had progression of disease with a median progression-free survival of 1.6 months and median overall survival of 3.9 months. Troglitazone does not seem to have activity in advanced colon cancer, although the lack of response may relate at least in part to the biologically aggressive nature of Stage IV colon cancer that is refractory to cytotoxic chemotherapy (the median number of prior chemotherapy regimens was 3). Although the study was not designed to assess troglitazone for possible tumor promoting effects, Kulke et al. urged caution in the use of PPAR\textgamma agonists in colon cancer. In the future, advances in the genomic profiling of colon cancer might allow for identification of susceptible colon cancer subtypes.

Colorectal cancer provides an excellent model of multistep progression in carcinogenesis, based on the acquisition of biochemical, molecular, and genetic alterations that transform normal epithelium to adenomatous polyps to invasive cancer [57]. PPAR\textgamma ligands may have a role in chemoprevention of colon cancer, depending on the specific molecular and genetic subtype. Thiazolidinediones suppress the development of aberrant crypt foci (ACF), a putative precancerous lesion of the colon [58]. However, activation of certain oncogenic signaling pathways at later stages of carcinogenesis may override this regulatory role, as suggested by the APC\textsuperscript{min/+} mouse studies [50]. Timing of PPAR\textgamma therapy prior to certain initiating events in colon carcinogenesis may thus prove to be useful for chemoprevention of colon cancer. As suggested by the in vivo studies of thiazolidinediones in min mice, use of PPAR\textgamma agonists in colon cancer prevention may require identification of high-risk individuals based on genetic susceptibility as well as aberrant gene expression and signal transduction.

Although the differentiating and antiproliferative effects of PPAR\textgamma activation form the basis for evaluating PPAR\textgamma ligands for cancer therapy, the anti-inflammatory effects of PPAR\textgamma may also be relevant to colon carcinogenesis. Chronic inflammation is linked to carcinogenesis, and diagnoses of inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, carry increased risk for colorectal cancer [59]. PPAR\textgamma ligands repress cytokine production by colon cancer cells and inhibit chemically-induced colitis in murine models of inflammatory bowel disease [60–62]. These findings led to an open-label pilot trial of rosiglitazone (4 mg taken twice daily) in patients with active ulcerative colitis for 12 weeks, showing clinical improvement in 8/15 (53%) patients of which 4 (27%) subjects had clinical remission [63]. Two subjects required hospitalization for worsening disease; other serious adverse events included severe pharyngitis requiring hospitalization and nephritic syndrome leading to withdrawal. The increased risk for colon cancer in patients with ulcerative colitis relates to the severity and duration of disease; by suppressing inflammation in the colon, drugs such as the thiazolidinediones or other PPAR\textgamma agonists might play a role in colon cancer prevention.

### 2.3. Breast cancer

In vitro and in vivo research studies support a role for PPAR\textgamma agonists in breast cancer therapy. Thiazolidinedione treatment of human breast cancer cells appears to induce changes suggestive of terminal differentiation, resulting in the inhibition of cell proliferation, suppression of keratin 19, mucin-1, and upregulation of maspin [28]. Troglitazone also inhibited breast cancer growth in a xenograft animal model [20]. Another synthetic ligand of PPAR\textgamma, GW7845, had inhibitory effects in a carcinogen-induced model of mammary tumorigenesis [64]. Furthermore, PPAR\textgamma haploinsufficiency (PPAR\textgamma+/−) conferred increased susceptibility to dimethylnitrosamine (DMBA)-induced mammary carcinogenesis [65]. These studies suggest that PPAR\textgamma ligands could serve as negative regulators of breast cancer development and progression.

We and others have demonstrated PPAR\textgamma immunostaining in human breast cancer specimens, as well as normal and benign proliferative breast tissue [28, 66]. PPAR\textgamma appears to be expressed in most if not all breast cancer cell lines, as well as in normal and malignant breast tissue [20, 28, 66]. We did not find that the invasive, metastatic phenotype of the breast cancer cells correlates with PPAR\textgamma expression levels, gel shift mobility patterns, or relative sensitivity to PPAR\textgamma ligands [67]. All of the cell lines tested (MCF-7, MDA-MB-436, MDA-MB-231, and MDA-MB-435) responded to thiazolidinedione treatment in transactivation assays, which also led to inhibition of cell growth.
However, a Phase II trial of troglitazone in metastatic breast cancer refractory to cytotoxic chemotherapy did not demonstrate beneficial effects on disease progression [68]. In twenty two Stage IV breast cancer patients with an 8-week median treatment duration, troglitazone at 800 mg/day did not prevent disease progression. The median time on study was 56 days, ranging from 11 to 134 days; 19/22 subjects were removed from the study for objective or subjective evidence of disease progression. There were no objective responses, and only 3/21 (14%) subjects completing 8 weeks of troglitazone therapy had stable disease. In patients with elevated serum levels of CEA and/or CA27.29 at the onset of the study, these tumor markers had continued to increase despite 8 weeks of troglitazone. Burstein et al. note that more selective criteria to target PPARγ therapy to the most susceptible tumor type might be helpful. The lack of effect might have also related to an advanced stage of disease that had become refractory to cytotoxic therapies.

To assess the effects of PPARγ ligand therapy on breast cancer, we conducted a pilot study of short-term administration of rosiglitazone (4 mg taken twice a day) to women newly diagnosed with early stage breast cancer (Stages 0 to II) during the two- to six-week period between diagnostic biopsy and surgical removal of the cancer [69]. Thirty eight women completed the study intervention without serious adverse events; thirty four subjects had sufficient pre and posttreatment tumor tissue for correlative analyses. By Ki67 immunostaining, short-term intervention with rosiglitazone did not lead to statistically significant differences cell proliferation. We did not detect any somatic or germline mutations in PPARG to account for differential tumor tissue responses or lack of effect. Comparing H&E-stained sections of tumor before and after rosiglitazone therapy also failed to note increased tumor cell differentiation by standard criteria of tubule formation, mitotic activity, and nuclear morphology. PPARγ expression in tumor samples was graded 0 to 3+ for intensity of nuclear and cytoplasmic immunostaining, which did not reflect an overall change in expression following rosiglitazone therapy. Interestingly, nuclear expression of PPARγ was significantly reduced in a majority of the patients whose pre-rosiglitazone PPARγ scores were 1+ or 2+ and therefore assessable for increased or decreased levels of expression, which raised the possibility of a PPARγ mediated response in the tumor tissue.

Serum levels of adiponectin and indices of insulin sensitivity increased with rosiglitazone, based on serum samples obtained from seventeen subjects. The association of lower levels of adiponectin and insulin resistance with increased breast cancer risk [70–73], therapy with rosiglitazone or other PPARγ ligands may have a role in breast cancer prevention. Of interest are potential effects of rosiglitazone therapy on nonepithelial components of the mammary tumor microenvironment; unfortunately, pretreatment core biopsy samples in our study had negligible to minimal stromal, noncancerous tissue for any comparative analyses.

Although short-term intervention with rosiglitazone did not alter the endpoint of cell proliferation, this pilot study indicated the potential for other tumor tissue specific effects with evidence for downregulation of PPARγ protein expression. Breast cancer is a family of diseases with diverse molecular, genetic features, and PPARγ ligands may affect only certain subtypes. Indeed, breast cancer therapy already encompasses molecularly targeted strategies, such as tamoxifen for estrogen receptor positive cancer and trastuzumab for tumors with HER-2/neu overexpression. Variability in PPARγ-mediated effects on cell proliferation could arise from tumor heterogeneity in nuclear receptor cross-talk, complement of cofactors, or mutated or aberrant signaling pathways that override PPARγ signaling, leading to an apparent lack of effect of rosiglitazone [74–77]. For example, in vitro studies indicate that estrogen receptor α (ERα) can repress PPARγ signaling by binding to PPREs and that PPAR/RXR heterodimers can competitively inhibit ER binding at specific estrogen response elements (EREs) [74, 75]. In vitro administration of the PPARγ ligand 15-deoxy-

2.4. Prostate cancer

PPARγ is expressed in human prostate cancer cell lines and human prostate cancer specimens [82]. In vitro and in vivo studies also demonstrate the anticancer effects of PPARγ ligands on prostate cancer, including the reduction of prostate specific antigen (PSA) levels in androgen responsive LNCaP cells [82–85].

A phase II clinical study assessed the effects of troglitazone at 800 mg/day in 41 men with androgen-dependent...
(n = 12) or androgen-independent prostate cancer (n = 29) that had progressed following local treatment or androgen deprivation therapy yet remained asymptomatic [82]. Four patients with androgen-dependent cancers had a reduction in serum PSA levels after onset of therapy, which were measured every 4 weeks, with a greater than 50% decrease in this tumor marker detected in one patient after 16 months of troglitazone. PSA levels decreased less than 50% in four patients with androgen-independent prostate cancer. The median duration of troglitazone treatment was longer in the androgen dependent (26.8 weeks) versus independent (14.3 weeks) group and could correlate with the more indolent course of disease associated with the former, as well as greater susceptibility of this prostate cancer subtype. As suggested by Mueller et al., variability in response might relate to activated mitogen-activated protein (MAP) kinase signaling leading to phosphorylation and inactivation of PPARγ as well as the possibility of somatic PPARG mutations.

Following from this initial study, a randomized placebo-controlled Phase II trial of rosiglitazone (8 mg/day) was conducted in prostate cancer patients with progressive disease evidenced by a rise in serum levels of PSA following local treatment with radical prostatectomy and/or radiation therapy [86]. 106 men participated in this multi-institutional study, with a median duration of 338 and 315 days of treatment for rosiglitazone and placebo, respectively. Based on serum PSA levels obtained every four weeks, rosiglitazone did not significantly increase the amount of time it took serum levels of PSA to double or increase the time before disease progression in men with prostate cancer. This trial does not support a role for rosiglitazone in recurrent prostate cancer, even if detected at the stage of biochemical, nonradiographic progression. Use of PPARγ ligands in prostate cancer may require identification of susceptible tumor subtypes as well as consideration of intervention at earlier stages of disease.

### 2.5. Thyroid cancer

The thyroid gland is comprised of follicle cells, which produce thyroglobulin as well as synthesize and store thyroxine, triiodothyronine, and parafollicular C cells that produce calcitonin. Papillary and follicular thyroid cancers arise from follicle cells, comprising 80–90% of thyroid cancers. Differentiated thyroid cancers usually retain the ability to take up iodine, which serves as the basis for (1) radioactive iodine treatments to ablate residual or metastatic disease and (2) diagnostic screening via radioiodine scans [87]. These thyroid cancers also produce thyroglobulin, and elevated thyroglobulin levels following definitive therapy can signify recurrent disease.

Normal, benign, and malignant thyroid tissues express PPARγ, with dysregulated expression in thyroid cancers [88, 89]. A PAX 8/PPARγ rearrangement has been noted in half of all follicular thyroid cancers, in which the resulting protein has a loss of PPARγ function [90]. Treatment of human thyroid cancer cells lines with thiazolidinediones inhibits cell proliferation and induces increased expression of markers of thyroid cell differentiation such as thyroglobulin, sodium-iodine symporter, thyroperoxidase, and TSH receptor [91–93].

These laboratory findings provided the basis for clinical investigation of the differentiating effects of PPARγ ligands in thyroid cancer. Philips et al. conducted a pilot trial of rosiglitazone therapy in five patients with thyroglobulin-positive and radioiodine-negative thyroid cancer, a clinical scenario suggestive of dedifferentiation of the thyroid cancer [94]. After three months of rosiglitazone (4 mg/day for one month, then 8 mg/day for 2 months), thyroglobulin levels increased in 4 of 5 patients but only one subject had faint radioiodine uptake to delineate two lung metastases. Kebebew et al. also administered rosiglitazone (4 mg/day for 1 week, then 8 mg/day for an additional 7 weeks) to patients with recurrent or progressive papillary or follicular thyroid cancer who had elevated serum thyroglobulin levels and negative radioiodine scans [95]. In this open label phase II trial, 4 of 10 (40%) of the subjects had posttreatment radioiodine scans showing uptake in the neck (n = 3) and pelvis (n = 1). At the six month follow-up visit, serum thyroglobulin changes did not reveal a consistent pattern, with decreased (n = 2), increased (n = 5), and stable (n = 3) levels. There were no complete responses, defined as increased radiiodine uptake and decreased thyroglobulin levels. PPARγ expression in pretreatment tumor samples by immunohistochemistry (formalin fixed, paraffin-embedded samples for eight patients) and real time quantitative RT-PCR (frozen samples for four subjects) did not correlate with the biological, biochemical responses. As noted in both reports, serum thyroglobulin level is somewhat problematic as a marker of differentiation in that increases could reflect re-differentiation/apoptosis as well as tumor progression. Future studies will also need to address heterogeneity of stage IV disease (e.g., some patients presented only with elevated thyroglobulin whereas others had diffuse metastases), dose level, duration of therapy, and intervention prior to development of metastases.

### 3. COMBINATION THERAPY

Despite the wealth of preclinical evidence for the anticancer effects of PPARγ ligands in various types of cancer, thiazolidinediones appear largely ineffective as monotherapy agents for treating advanced, disseminated stages of cancer. However, cancer chemotherapy often involves the concomitant and/or sequential administration of multiple drugs in order to achieve maximal tumor cell kill and improved disease-free and overall survival. Combinatorial drug regimens may allow for additive if not synergistic effects which might also permit the use of lower dosages with decreased side effects. Preclinical studies show the potential benefits of combining PPARγ ligands with other anticancer agents. For example, rosiglitazone treatment of A549 lung cancer cells increases the expression of PTEN (phosphatase and tensin homolog), which enhances the antiproliferative effects of the tyrosine kinase inhibitor gefitinib [96]. The combination of rosiglitazone and platinum-based cytotoxic drugs such as carboplatin and cisplatin synergistically inhibits the growth...
of A549 lung cancer cells relative to single-agent therapy [97]. Based on gene array analysis, rosiglitazone appears to mediate the downregulation of metallothioneins, heavy metal binding proteins involved in platinum drug resistance.

Lack of effect of PPARγ ligand therapy may also relate to repression of ligand activation, such as by histone deacetylases (HDAC) which can form complexes with PPARγ to repress gene transcription of specific PPARγ target genes [98]. Removal of HDAC-mediated transcriptional silencing may allow activation of PPARγ and macrophages [36, 103, 104], and thiazolidinediones to suppress the proinflammatory potential of monocytes [113].

Combination of PPARγ via phosphorylation could also occur in cancers with high levels of activity of mitogen-activated protein kinase [99], and coadministration of inhibitors of specific kinases might enhance the therapeutic potential of a PPARγ agonist.

Novel treatment regimens combining pioglitazone with the COX-2 inhibitor rofecoxib and low-dose continuous chemotherapy drugs have been tested for efficacy in aggressive solid malignancies at advanced, progressive stages of disease. In a pilot study of 6 patients with advanced malignant vascular tumors that had progressed following surgery, radiotherapy, and/or chemotherapy, treatment with pioglitazone (45 mg/day), rofecoxib (25 mg/day), and metronomic trofosfamide (3×50 mg/day) resulted in 2 subjects with complete responses, 1 with a partial response, and 3 with stable disease [100]. The median progression-free survival was 7.7 months (range of 2 to 15 months), and the average treatment duration was 29.3, 21.7, and 23 weeks for pioglitazone, rofecoxib, and trofosfamide, respectively. Interestingly, one subject experienced regression of an extensive angiosarcoma of the facial skin with initiation of therapy with pioglitazone and rofecoxib alone. The Phase II trial of this treatment regimen in a cohort of patients with progression of previously treated metastatic melanoma (n = 19) or soft tissue sarcoma (n = 21) led to decreased tumor burden in 5 subjects and stabilization of disease in 6 subjects [101]. More recently, a multi-institutional randomized clinical trial of trofosfamide (50 mg TID) versus trofosfamide (50 mg TID) plus rofecoxib (25 mg/day) and pioglitazone (60 mg/day) of 76 patients with metastatic melanoma demonstrated superiority of metronomic chemotherapy combined with a COX-2 inhibitor and PPARγ ligand, with 0% versus 9% progression-free survival [102]. Assessment of serum C reactive protein (CRP) levels in 48 subjects participating in this melanoma trial showed that those on the combined regimen had a greater than 30% decrease in this proinflammatory marker, suggesting that the anti-inflammatory effects of the drug combination may account for the improvement in progression-free survival. Interestingly, PPARγ appears to suppress the proinflammatory potential of monocytes and macrophages [36, 103, 104], and thiazolidinediones have been shown to decrease CRP levels [105]. Another metronomic, low-dose chemotherapy regimen of either capecitabine (1250 mg/m² twice daily for days 1–14 of 21 days) or temozolomide (50 mg/m²/day) combined with pioglitazone (60 mg/d) and rofecoxib (25 mg/d) was tested in patients who had developed recurrent high-grade gliomas (10 with glioblastoma, 4 with anaplastic astrocytoma) following chemotherapy, surgery, and/or radiotherapy, with 21.5% overall progression-free survival at six months (20% and 25% PFS for subjects with glioblastoma and anaplastic gliomas, resp.) [106]. By immunostaining the expression of COX-2, PPARγ, and CD31 in these high-grade gliomas did not correlate with patient outcome; however, as recurrence was diagnosed by magnetic resonance imaging, tumor tissue obtained prior to disease progression might not accurately represent target gene expression in the recurrent tumors.

The contribution of pioglitazone to the activity of these combination regimens is difficult to assess but may relate to anti-inflammatory effects as suggested by the CRP results in metastatic melanoma. PPARγ ligands are also known to exert suppressive effects on angiogenesis in cancer [34] and on malignant vascular cells [107], which may also enhance the effectiveness of metronomic chemotherapy regimens for certain malignancies.

Combination with ligands to retinoid X receptor (RXR), the heterodimer partner of PPARγ, may also augment the anticancer efficacy of PPAR ligand therapy. Treatment with RXR ligands alone appears efficacious in the treatment of certain malignancies, and bexarotene (Targretin) is a synthetic RXR-selective retinoid utilized in the treatment of refractory cutaneous T-cell lymphoma [108]. A Phase I study of bexarotene in patients with advanced cancer did not show objective tumor responses but indicated the potential for stable disease in 5 of 16 and 1 of 5 lung and head and neck cancer patients, respectively [109]. In a multi-institutional Phase II trial of bexarotene capsules (MINT or Targretin Monotherapy in non-small-cell lung cancer trial) in advanced non-small-cell lung cancer patients who had failed two or more prior chemotherapy regimens, bexarotene (400 mg/m²/day) did not meet the intended aim of a median survival of 6 months as third-line therapy; however, the subset of subjects with treatment-related hyperglycemia (grade 1 to 4, 51%) and/or skin reactions such as rash, pruritis, and erythema (grade 1 to 4, 28%) had prolonged survival at one year of 30% and 34%, respectively, compared to 18% and 19%, respectively, of patients without these adverse events [110]. A role for bexarotene as monotherapy is also demonstrated in preclinical models of mammary carcinogenesis [111, 112]. A Phase II randomized trial of 200 or 500 mg/m²/day bexarotene in women with metastatic breast cancer refractory to endocrine therapy or chemotherapy showed clinical benefit in the form of complete/partial response and stable disease ≥ 6 months in 27 of 146 patients, with an objective response rate of 3 to 6% [113].

To evaluate RXR-PPARγ ligand therapy for synergism in cutaneous T-cell lymphoma, a small uncontrolled study evaluated the addition of rosiglitazone to bexarotene monotherapy in four patients with stable or progressive cutaneous T-cell lymphoma, showing improvement in skin score (50%) and pruritus (75%) [114]. Preclinical studies of solid malignancies such as liposarcomas, breast, and colon cancers also provide support for the greater efficacy of combined regimens of PPARγ and RXR ligands compared to monotherapy [26, 80, 115]. In addition to increased
therapeutic benefits, combination therapy may also allow for lower doses and decreased toxicity.

Novel cancer agents that combine PPARγ agonism with inhibition of other signaling pathways are also of interest. LY293111 is a diaryl ether carboxylic acid derivative that modulates multiple eicosanoid pathways, acting as a leukotriene B4 antagonist, 5-lipoxygenase inhibitor, and PPARγ agonist [116]. Phase I trials have identified the maximally tolerated dose for continuous oral administration of LY293111, both as a single agent and in combination with irinotecan for solid malignancies [116]. Future clinical trials with correlative tissue analyses may provide insight into the specific contribution of PPARγ agonism to the therapeutic potential of LY293111.

4. CANCER PREVENTION

PPARγ may function as a tumor suppressor during early events of carcinogenesis. Thiazolidinediones or other PPARγ ligands may have efficacy during early stages of cancer development, by targeting carcinogenesis prior to onset of initiating events that are no longer subject to PPARγ repression. Indeed, mutant APC function and dysregulated β-catenin signaling in the APC+/−/min mice model of colon carcinogenesis appear to abrogate responsiveness to PPARγ activation [50]. Susceptibility to PPARγ ligands is possibly limited to only certain premalignant conditions or individuals, and development of genomic strategies to properly apply this chemopreventive option in an otherwise heterogeneous high-risk population is needed.

In a phase II clinical trial of pioglitazone therapy for dysplastic leukoplakia, a precursor lesion to invasive oral cancer, pioglitazone administered for 3 months at 45 mg/day elicited a response in 70% of subjects (15/21) based on bidimensional measurements of the oral lesions [117]. Although the degree of dysplasia increased in three subjects, pioglitazone did not alter the degree of dysplasia in the majority of patients. These findings raise the possibility that PPARγ ligands may prove efficacious for chemoprevention of oral cancer by decreasing the extent of leukoplakia. The lack of effect on dysplasia suggests that pioglitazone may not function as a differentiating agent for oral leukoplakia or at least within the time frame of a three month intervention.

5. SAFETY AND TOXICITY ISSUES

Even though the risk-benefit ratio of thiazolidinediones for cancer therapy seems favorable for advanced stages of disease, thiazolidinediones appear problematic as candidate agents for chemoprevention rather than for treatment of advanced, metastatic cancer. Use of thiazolidinediones in adjuvant therapy for cancer patients who are otherwise healthy but at increased risk for cancer recurrence would also raise concerns if administered on a long-term basis as for a chronic disease such as diabetes mellitus. Although generally well-tolerated, thiazolidinediones such as rosiglitazone and pioglitazone are associated with body weight gain as a result of increased adiposity and fluid retention, with the latter resulting in peripheral edema, anemia on the basis of hemodilution, and increased risk of developing congestive heart failure [118–120]. Controversy currently exists regarding the cardiovascular safety of rosiglitazone, with a recent meta-analysis of different treatment trials of rosiglitazone suggesting that rosiglitazone was associated with a significant increase in the risk of myocardial infarction and cardiovascular death [121]. However, other studies have not shown an increased risk of cardiovascular mortality, including the interim analysis of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) trial, a prospective trial of rosiglitazone in type 2 diabetes mellitus [122, 123]. For postmenopausal women, rosiglitazone therapy has also been linked to osteoporosis and risk of fracture [124]. Such side effects are concerning for healthy individuals contemplating cancer risk reduction rather than treatment of disease. Defining the risks of thiazolidinediones will allow for avoidance of these drugs in subjects at higher risk for these associated complications.

The carcinogenic potential of thiazolidinediones and other PPARγ agonists is another point of controversy [125, 126]. Upon review of the carcinogenicity of PPARγ and dual PPARα/γ agonists in development, the US Food and Drug Administration has recommended two-year carcinogenicity studies of new PPAR agonist drugs in rodents prior to initiation of clinical trials longer than six months [127, 128]. As discussed above, contradictory in vivo and in vitro findings may relate to specific animal models or molecular, genetic subtypes of certain cancers. Additionally, as diabetes and insulin resistance have been linked to higher risk for certain malignancies such as breast and colon cancer [72, 129, 130], thiazolidinediones might even exert preventive effects on carcinogenesis by ameliorating the chronic inflammation associated with dysregulated metabolism.

Postmarketing experience with pioglitazone and rosiglitazone has not shown significantly increased cancer risk with these drugs. The PROActive Study (PROspective pioglitazone clinical trial In macrovascular events), which randomized 5238 patients with type 2 diabetes mellitus and cardiovascular or peripheral vascular disease to pioglitazone or placebo for an average of 34.5 months, did not detect differences in the overall number of malignancies [131]. Interestingly, the pioglitazone treated group had more bladder tumors (14 versus 6) and fewer breast cancers (3 versus 11); however, the timing of the cancer diagnoses relative to pioglitazone use and the presence of confounding risk factors did not support a causal relationship to the study drug. Use of thiazolidinediones was associated with 33% decreased risk for lung cancer in a large retrospective database analysis of over 87,000 diabetic patients of 10 veteran affairs medical centers, without significant risk reduction for colorectal and prostate cancer [132]. Whether lung cancer is uniquely susceptible to thiazolidinediones or other PPARγ agonists remains to be determined; preclinical studies suggest a potential role for PPARγ ligand therapy in the management of this disease [133, 134]. In the preliminary report of a more recent analysis of this Veteran Affairs database, thiazolidinedione use also correlated with 41 to 55% reduced risk for head and neck squamous cell carcinoma [135]. Conversely, a smaller retrospective study of 1003 diabetic subjects in the
Vermont diabetes information system database showed a possible association of cancer with use of thiazolidinediones and particularly rosiglitazone, based on self reported history of malignancy of any type [136]. Prospective studies with attention to confounding influences such as risk factors or timing and duration of drug use relative to cancer diagnosis are needed to investigate these possible associations and basis for the discrepant findings.

6. CONCLUSIONS

Based on the clinical experience to date, use of PPARγ agonists in cancer therapy will likely require a targeted approach, with restriction to specific types of malignancies and/or stage(s) of disease susceptible to enhanced PPARγ signaling. Studies of PPARγ ligand therapy in cancer patients have focused largely on thiazolidinediones approved for treatment of type 2 diabetes mellitus, administered at the high end of doses tested for tolerability and insulin sensitizing effects. In phase II clinical trials, thiazolidinediones do not have significant activity in most cancers at advanced stages, which may relate to the extent and burden of disease and aggressive tumor phenotypes resistant to cytotoxic therapies. The lack of efficacy of thiazolidinediones in advanced, metastatic disease may relate to the use of noncytotoxic dose levels; alternatively, these drugs may not exert effects at late stages of cancer progression at any dose level. However, the demonstration of differentiating effects in some patients suggests that a subset of patients might benefit from PPARγ ligand therapy. Thiazolidinediones and other PPARγ agonists may ultimately prove effective in combination with standard cytotoxic agents or other molecularly targeted therapies. Interventions at earlier stages of disease, including premalignant or predisposing high-risk conditions, should also be considered. Therapy administered in the adjuvant setting, such as following surgical resection, or in situations of microscopic rather than measurable disease may also have greater efficacy. The use of PPARγ ligands in earlier stages of cancer or cancer prevention will require additional research and/or drug development to address the questions regarding the carcinogenic potential and other adverse effects of these drugs. Genetic and molecular profiling of human cancers may in the future enable selection of a tumor subtype susceptible to PPARγ agonists, as specific genotypes and patterns of nuclear receptor and cofactor expression might predict resistance or responsiveness to PPARγ signal transduction.

ACKNOWLEDGMENTS

Research in the laboratory of LDY was supported by grants from the National Cancer Institute of the NIH (K07 CA86020) and the Department of Defense (DAMD 170110357). Portions of this work were also supported by the General Clinical Research Center at The Ohio State University, Grant no. M01-RR00034 from the National Center of Research Resources of the NIH.

REFERENCES

[1] D. J. Mangelsdorf, C. Thummel, M. Beato, et al., "The nuclear receptor superfamily: the second decade," Cell, vol. 83, no. 6, pp. 835–839, 1995.
[2] W. Wahli and E. Martinez, “Superfamily of steroid nuclear receptors: positive and negative regulators of gene expression,” The FASEB Journal, vol. 5, no. 9, pp. 2243–2249, 1991.
[3] S. A. Kliewer, B. M. Forman, B. Blumberg, et al., "Differential expression and activation of a family of murine peroxisome proliferator-activated receptors," Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 15, pp. 7355–7359, 1994.
[4] G. Krey, H. Keller, A. Mahfoudi, et al., “Xenopus peroxisome proliferator activated receptors: genomic organization, response element recognition, heterodimer formation with retinoid X receptor and activation by fatty acids,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 47, no. 1–6, pp. 65–73, 1993.
[5] K. L. Gearing, M. Göttlicher, M. Teboul, E. Widmark, and I. A. Gustafsson, "Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor," Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 4, pp. 1440–1444, 1993.
[6] S. A. Kliewer, K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans, “Convergence of 9-cis retinoid acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors," Nature, vol. 358, no. 6389, pp. 771–774, 1992.
[7] P. Tontonoz, E. Hu, R. A. Graves, A. L. Budavari, and B. M. Spiegelman, "mPPARγ2: tissue-specific regulator of an adipocyte enhancer," Genes & Development, vol. 8, no. 10, pp. 1224–1234, 1994.
[8] P. Tontonoz, E. Hu, and B. M. Spiegelman, "Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor," Cell, vol. 79, no. 7, pp. 1147–1156, 1994.
[9] E. D. Rosen, P. Sarraf, A. E. Troy, et al., “PPARγ is required for the differentiation of adipose tissue in vivo and in vitro," Molecular Cell, vol. 4, no. 4, pp. 611–617, 1999.
[10] I. Issemann and S. Green, "Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators," Nature, vol. 347, no. 6294, pp. 645–650, 1990.
[11] C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli, "Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors," Cell, vol. 68, no. 5, pp. 879–887, 1992.
[12] H. Keller, C. Dreyer, J. Medin, A. Mahfoudi, K. Ozato, and W. Wahli, "Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers," Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 6, pp. 2160–2164, 1993.
[13] G. Krey, O. Braissant, F. L’Horset, et al., “Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay," Molecular Endocrinology, vol. 11, no. 6, pp. 779–791, 1997.
[14] S. A. Kliewer, S. S. Sundseth, S. A. Jones, et al., “Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors a and y," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4318–4323, 1997.
[15] S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann, "A prostaglandin J2..."
metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation,” Cell, vol. 83, no. 5, pp. 813–819, 1995.

[16] B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ,” Cell, vol. 83, no. 5, pp. 803–812, 1995.

[17] L. Nagy, P. Tontonoz, J. G. A. Alvarez, H. Chen, and R. M. Evans, “Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ,” Cell, vol. 93, no. 2, pp. 229–240, 1998.

[18] J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Klierwe, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” The Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995.

[19] J. M. Lehmann, J. M. Lenhard, B. B. Oliver, G. M. Ringold, and S. A. Klierwe. “Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs,” The Journal of Biological Chemistry, vol. 272, no. 6, pp. 3406–3410, 1997.

[20] E. Ehntser, C. Müller, K. Koshizuka, et al., “Ligands for peroxisome proliferator-activated receptor and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 15, pp. 8806–8811, 1998.

[21] J. A. Keelan, T. A. Sato, K. W. Marvin, J. Lander, R. S. Gilmour, and M. D. Mitchell, “15-deoxy-Δ12,14-prostaglandin J2: a ligand for peroxisome proliferator-activated receptor-γ, induces apoptosis in JEG3 chorionicarcinoma cells,” Biochemical and Biophysical Research Communications, vol. 262, no. 3, pp. 579–585, 1999.

[22] N. Takahashi, T. Okumura, W. Motomura, Y. Fujimoto, I. Kawabata, and Y. Kohgo, “Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells,” FEBS Letters, vol. 455, no. 1-2, pp. 135–139, 1999.

[23] C. E. Clay, A. M. Namen, G. Atsumi, et al., “Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells,” Carcinogenesis, vol. 20, no. 10, pp. 1905–1911, 1999.

[24] J. Padilla, K. Kaur, H. J. Cao, T. J. Smith, and R. P. Phipps, “Peroxisome proliferator activator receptor-γ agonists and 15-deoxy-Δ12,14-PGJ2 induce apoptosis in normal and malignant B lineage cells,” The Journal of Immunology, vol. 165, no. 12, pp. 6941–6948, 2000.

[25] F. Yin, S. Wakino, Z. Liu, et al., “Trogltizone inhibits growth of MCF-7 human breast carcinoma cells by targeting G1 cell cycle regulators,” Biochemical and Biophysical Research Communications, vol. 286, no. 5, pp. 916–922, 2001.

[26] P. Tontonoz, S. Singer, B. M. Forman, et al., “Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 1, pp. 237–241, 1997.

[27] P. Sarraf, E. Mueller, D. Jones, et al., “Differentiation and reversal of malignant changes in colon cancer through PPARγ,” Nature Medicine, vol. 4, no. 9, pp. 1046–1052, 1998.

[28] E. Mueller, P. Sarraf, P. Tontonoz, et al., “Terminal differentiation of human breast cancer through PPARγ,” Molecular Cell, vol. 1, no. 3, pp. 465–470, 1998.

[29] S. Kitamura, Y. Miyazaki, Y. Shinomura, S. Kondo, S. Kanayama, and Y. Matsuzawa, “Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells,” Japanese Journal of Cancer Research, vol. 90, no. 1, pp. 75–80, 1999.

[30] S. W. Han, M. E. Greene, J. Pitts, R. K. Wada, and N. Sidell, “Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARγ) in human neuroblastoma cells,” Clinical Cancer Research, vol. 2, no. 1, pp. 98–104, 2001.

[31] S. Goetze, X.-P. Xi, H. Kawano, et al., “PPARγ ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells,” Journal of Cardiovascular Pharmacology, vol. 33, no. 5, pp. 798–806, 1999.

[32] X. Xin, S. Yang, J. Kowalski, and M. E. Gerritsen, “Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo,” The Journal of Biological Chemistry, vol. 274, no. 13, pp. 9116–9121, 1999.

[33] D. Bishop-Bailey and T. Hla, “Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12,14-prostaglandin J2,” The Journal of Biological Chemistry, vol. 274, no. 24, pp. 17042–17048, 1999.

[34] D. Panigrahy, S. Singer, L. Q. Shen, et al., “PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis,” The Journal of Clinical Investigation, vol. 110, no. 7, pp. 923–932, 2002.

[35] H. Huang, S. C. Campbell, D. F. Bedford, et al., “Peroxisome proliferator-activated receptor γ ligands improve the antitumor efficacy of thombospodind peptide ABT1510,” Molecular Cancer Research, vol. 2, no. 10, pp. 541–550, 2004.

[36] M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998.

[37] C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998.

[38] N. Marx, G. Sukhova, C. Murphy, P. Libby, and J. Plutzky, “Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro,” American Journal of Pathology, vol. 153, no. 1, pp. 17–23, 1998.

[39] L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002.

[40] A. J. Scheen, “Thiazolidinediones and liver toxicity,” Diabetes and Metabolism, vol. 27, no. 3, pp. 305–313, 2001.

[41] T. Mentzel and C. D. M. Fletcher, “Lipomatous tumours of soft tissues: an update,” Virchows Archiv, vol. 427, no. 4, pp. 353–363, 1995.

[42] K. M. Dalal, C. R. Antonescu, and S. Singer, “Diagnosis and management of lipomatous tumors,” Journal of Surgical Oncology, vol. 97, no. 4, pp. 298–313, 2008.

[43] A. E. Horvai, J. T. Schaefer, E. K. Nakakura, and R. J. O’Donnell, “Immunostaining for peroxisome proliferator-gamma distinguishes desdifferentiated liposarcoma from other retroperitoneal sarcomas,” Modern Pathology, vol. 21, no. 5, pp. 517–524, 2008.

[44] G. D. Demetri, C. D. M. Fletcher, E. Mueller, et al., “Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor γ ligand troglitazone in patients with liposarcoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 7, pp. 3951–3956, 1999.

[45] G. Debrock, V. Vanhentenriijn, R. Sicot, M. Debiec-Rychter, R. Oyen, and A. Van Oosterom, “A phase II trial with
rosiglitazone in liposarcoma patients,” British Journal of Cancer, vol. 89, no. 8, pp. 1409–1412, 2003.

[46] R. N. DuBois, R. Gupta, J. Brockman, B. S. Reddy, S. L. Krakow, and M. A. Lazar, “The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers,” Carcinogenesis, vol. 19, no. 1, pp. 49–53, 1998.

[47] R. A. Gupta, J. A. Brockman, P. Sarraf, T. M. Willson, and R. N. DuBois, “Target genes of peroxisome proliferator-activated receptor γ in colorectal cancer cells,” The Journal of Biological Chemistry, vol. 276, no. 32, pp. 29681–29687, 2001.

[48] A.-M. Lefebvre, I. Chen, P. Desreumaux, et al., “Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APC+/+ mice,” Nature Medicine, vol. 4, no. 9, pp. 1053–1057, 1998.

[49] E. Saez, P. Tontonoz, M. C. Nelson, et al., “Activators of the nuclear receptor PPARγ enhance colon polyf formation,” Nature Medicine, vol. 4, no. 9, pp. 1058–1061, 1998.

[50] G. D. Gurnan, W. M. Smith, S. Drori, et al., “APC-dependent suppression of colon carcinogenesis by PPARγ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 21, pp. 13771–13776, 2002.

[51] N. Niho, M. Takahashi, T. Kitamura, et al., “Concomitant suppression of hyperlipidemia and intestinal polyf formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands,” Cancer Research, vol. 63, no. 18, pp. 6090–6095, 2003.

[52] N. Niho, M. Takahashi, Y. Shoji, et al., “Dose-dependent suppression of hyperlipidemia and intestinal polyf formation in Min mice by pioglitazone, a PPARγ ligand,” Cancer Science, vol. 94, no. 11, pp. 960–964, 2003.

[53] P. Sarraf, E. Mueller, W. M. Smith, et al., “Loss-of-function mutations in PPARγ associated with human colon cancer,” Molecular Cell, vol. 3, no. 6, pp. 799–804, 1999.

[54] R. A. Gupta, P. Sarraf, E. Mueller, et al., “Peroxisome proliferator-activated receptor γ-mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms,” The Journal of Biological Chemistry, vol. 278, no. 25, pp. 22669–22677, 2003.

[55] D. Bouanchoe, B. Buecher, A. Jarry, et al., “The PPARγ K422Q mutation does not contribute to troglitazone inefficiency in colon cancer treatment,” Cancer Letters, vol. 224, no. 1, pp. 111–116, 2005.

[56] M. H. Kulke, G. D. Demetri, N. E. Sharpless, et al., “A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer,” Cancer Journal, vol. 8, no. 5, pp. 395–399, 2002.

[57] B. Vogelstein, E. R. Fearon, S. R. Hamilton, et al., “Genetic alterations during colorectal-tumor development,” The New England Journal of Medicine, vol. 319, no. 9, pp. 525–532, 1988.

[58] E. Osawa, A. Nakajima, K. Wada, et al., “Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice,” Gastroenterology, vol. 124, no. 2, pp. 361–367, 2003.

[59] J. D. Lewis, J. J. Deren, and G. R. Lichtenstein, “Cancer risk in patients with inflammatory bowel disease,” Gastroenterology Clinics of North America, vol. 28, no. 2, pp. 459–477, 1999.

[60] C. G. Su, X. Wen, S. T. Bailey, et al., “A novel therapy for colitis utilizing PPARγ ligands to inhibit the epithelial inflammatory response,” The Journal of Clinical Investigation, vol. 104, no. 4, pp. 383–389, 1999.

[61] T. Tanaka, H. Kohno, S.-I. Yoshitani, et al., “Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats,” Cancer Research, vol. 61, no. 6, pp. 2424–2428, 2001.

[62] M. Sánchez-Hidalgo, A. R. Martin, I. Villegas, and C. Alarcón De La Lastra, “Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats,” Biochemical Pharmacology, vol. 69, no. 12, pp. 1733–1744, 2005.

[63] J. D. Lewis, G. R. Lichtenstein, R. B. Stein, et al., “An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis,” The American Journal of Gastroenterology, vol. 96, no. 12, pp. 3323–3328, 2001.

[64] N. Suh, Y. Wang, C. R. Williams, et al., “A new ligand for the peroxisome proliferator-activated receptor-γ (PPARγ), GW7845, inhibits rat mammary carcinogenesis,” Cancer Research, vol. 59, no. 22, pp. 5671–5673, 1999.

[65] C. J. Nicol, M. Yoon, J. M. Ward, et al., “PPARα influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis,” Carcinogenesis, vol. 25, no. 9, pp. 1747–1755, 2004.

[66] L. D. Yee, Y. Guo, J. Bradford, S. Suster, S. K. Clinton, and V. L. Seewaldt, “The antiproliferative effects of PPARγ ligands in normal human mammary epithelial cells,” Breast Cancer Research and Treatment, vol. 78, no. 2, pp. 179–192, 2003.

[67] L. D. Yee, C. L. Sabourin, L. Liu, et al., “Peroxisome proliferator-activated receptor gamma activation in human breast cancer,” International Journal of Oncology, vol. 15, no. 5, pp. 967–973, 1999.

[68] H. J. Burstein, G. D. Demetri, E. Mueller, P. Sarraf, B. M. Spiegelman, and E. P. Winer, “Use of the peroxisome proliferator-activated receptor (PPARγ) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study,” Breast Cancer Research and Treatment, vol. 79, no. 3, pp. 391–397, 2003.

[69] L. D. Yee, N. Williams, P. Wen, et al., “Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers,” Clinical Cancer Research, vol. 13, no. 1, pp. 246–252, 2007.

[70] Y. Miyoshi, T. Funahashi, S. Kihara, et al., “Association of serum adiponectin levels with breast cancer risk,” Clinical Cancer Research, vol. 9, no. 15, pp. 5699–5704, 2003.

[71] C. Mantzoros, E. Petridou, N. Desypris, et al., “Adiponectin and breast cancer risk,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 3, pp. 1102–1107, 2004.

[72] P. F. Bruning, J. M. G. Bonfrer, P. A. H. van Noord, A. A. A. Nijenhuis, M. de Jong-Bakker, and W. J. Nooijen, “Insulin resistance and breast-cancer risk,” International Journal of Cancer, vol. 52, no. 4, pp. 511–516, 1992.

[73] B. A. Stoll, “Upper abdominal obesity, insulin resistance and breast cancer risk,” International Journal of Obesity, vol. 26, no. 6, pp. 747–753, 2002.

[74] H. Keller, F. Givel, M. Perroud, and W. Wahl, “Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements,” Molecular Endocrinology, vol. 9, no. 7, pp. 794–804, 1995.

[75] D. Bonofiglio, S. Gabriele, S. Aquila, et al., “Estrogen receptor α binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor γ signaling in breast cancer cells,” Clinical Cancer Research, vol. 11, no. 17, pp. 6139–6147, 2005.

[76] H. Zhang, S.-Q. Kuang, L. Liao, S. Zhou, and J. Xu, “Haploid inactivation of the amplified-in-breast cancer 3 coactivator
reduces the inhibitory effect of peroxisome proliferator-activated receptor γ and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice," *Cancer Research*, vol. 64, no. 19, pp. 7169–7177, 2004.

[77] R. E. Teresi, C.-W. Shiu, C.-S. Chen, V. K. Chatterjee, K. A. Waite, and C. Eng, "Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and Rosiglitazone," *International Journal of Cancer*, vol. 118, no. 10, pp. 2390–2398, 2006.

[78] T. Suzuki, S. Hayashi, Y. Miki, et al., "Peroxisome proliferator-activated receptor γ in human breast carcinoma: a modulator of estrogenic actions," *Endocrine-Related Cancer*, vol. 13, no. 1, pp. 233–250, 2006.

[79] I. Papadaki, E. Mylona, I. Giannopoulou, S. Markaki, A. Keramopoulos, and L. Nakopoulos, "PPARγ expression in breast cancer: clinical value and correlation with ERβ," *Histopathology*, vol. 46, no. 1, pp. 37–42, 2005.

[80] E. Elstner, E. A. Williamson, C. Zang, et al., "Novel therapeutic approach: ligands for PPARγ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells," *Breast Cancer Research and Treatment*, vol. 74, no. 2, pp. 155–165, 2002.

[81] M. Hedvat, A. Jain, D. A. Carson, et al., "Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARγ," *Cancer Cell*, vol. 5, no. 6, pp. 565–574, 2004.

[82] E. Mueller, M. Smith, P. Sarraf, et al., "Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 20, pp. 10990–10995, 2000.

[83] T. Kubota, K. Koshizuka, E. A. Williamson, et al., "Ligand for peroxisome proliferator-activated receptor γ (Troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo," *Cancer Research*, vol. 58, no. 15, pp. 3344–3352, 1998.

[84] R. Butler, S. H. Mitchell, D. I. Tindall, and C. Y. F. Young, "Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-deoxy-Δ12,14-prostaglandin J2," *Cell Growth & Differentiation*, vol. 11, no. 1, pp. 49–61, 2000.

[85] J.-S. Annicotte, I. Iankova, S. Miard, et al., "Peroxisome proliferator-activated receptor γ regulates E-cadherin expression and inhibits growth and invasion of prostate cancer," *Molecular and Cellular Biology*, vol. 26, no. 20, pp. 7561–7574, 2006.

[86] M. R. Smith, J. Manola, D. S. Kaufman, et al., "Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy," *Cancer*, vol. 101, no. 7, pp. 1569–1574, 2004.

[87] E. L. Mazzaferrri, "An overview of the management of papillary and follicular thyroid carcinoma," *Thyroid*, vol. 9, no. 5, pp. 421–427, 1999.

[88] A. R. Marques, C. Espadinha, M. J. Frias, et al., "Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours," *British Journal of Cancer*, vol. 91, no. 4, pp. 732–738, 2004.

[89] S. Karger, K. Berger, M. Eszlinger, et al., "Evaluation of peroxisome proliferator-activated receptor-γ expression in benign and malignant thyroid pathologies," *Thyroid*, vol. 15, no. 9, pp. 997–1003, 2005.
of Clinical Endocrinology & Metabolism, vol. 89, no. 6, pp. 2728–2735, 2004.

[106] P. Hau, L. Kunz-Schughart, U. Bogdahn, et al., “Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas—a phase II study,” *Oncology*, vol. 73, no. 1-2, pp. 21–25, 2007.

[107] P. Dittmar, A. Vanbuskirk, and L. Yee, “Antiangiogenic effects of PPARy ligands on EOMA endothelial cells,” in *Proceedings of the 94th American Association for Cancer Research Annual Meeting (AACR '03)*, p. 605, Washington, DC, USA, July 2003.

[108] M. Duvic, A. G. Martin, Y. Kim, et al., “Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma,” *Archives of Dermatology*, vol. 137, no. 5, pp. 581–593, 2001.

[109] N. A. Rizvi, J. L. Marshall, W. Dahut, et al., “A phase I study of LGD1069 in adults with advanced cancer,” *Clinical Cancer Research*, vol. 5, no. 7, pp. 1658–1664, 1999.

[110] R. Govindan, J. Crowley, L. Schwartzberg, et al., “Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies,” *Journal of Clinical Oncology*, vol. 24, no. 30, pp. 4848–4854, 2006.

[111] M. M. Gottardis, E. D. Bischot, M. A. Shirley, M. A. Wagoner, W. W. Lampf, and R. A. Heyman, “Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand,” *Cancer Research*, vol. 56, no. 24, pp. 5566–5570, 1996.

[112] K. Wu, Y. Zhang, X.-C. Xu, et al., “The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice,” *Cancer Research*, vol. 62, no. 22, pp. 6376–6380, 2002.

[113] F. J. Esteva, J. Glaspy, S. Baidas, et al., “Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer,” *Journal of Clinical Oncology*, vol. 21, no. 6, pp. 999–1006, 2003.

[114] J. A. Sepmeyer, J. P. Greer, T. Koyama, and J. A. Zic, “Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma,” *Journal of the American Academy of Dermatology*, vol. 56, no. 4, pp. 584–587, 2007.

[115] R. M. Cesario, J. Stone, W.-C. Ye, R. P. Rissonnette, and W. W. Lampf, “Differentiation and growth inhibition mediated via the RXR:PPAR heterodimer in colon cancer,” *Cancer Letters*, vol. 240, no. 2, pp. 225–233, 2006.

[116] T. Baetz, E. Eisenhauer, L. Siu, et al., “A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours,” *Investigational New Drugs*, vol. 25, no. 3, pp. 217–225, 2007.

[117] F. G. Ondrey, “Pioglitazone in oral leukoplakia: a phase II trial,” in *Proceedings of the American Association for Cancer Research International Conference: Frontiers in Cancer Prevention Research*, p. 170, Philadelphia, PA, USA, December 2007.

[118] L. L. Lipscombe, T. Gomes, L. E. Lévesque, J. E. Hux, D. N. Juurlink, and D. A. Alter, “Thiazolidinediones and cardiovascular outcomes in older patients with diabetes,” *The Journal of the American Medical Association*, vol. 298, no. 22, pp. 2634–2643, 2007.

[119] S. Singh, Y. K. Loke, and C. D. Furberg, “Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis,” *The Journal of the American Medical Association*, vol. 298, no. 10, pp. 1189–1195, 2007.

[120] A. M. Lincoff, K. Wolski, S. J. Nicholls, and S. E. Nissen, “Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials,” *The Journal of the American Medical Association*, vol. 298, no. 10, pp. 1180–1188, 2007.

[121] S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” *The New England Journal of Medicine*, vol. 356, no. 24, pp. 2457–2471, 2007.

[122] G. A. Diamond, L. Bax, and S. Kaul, “Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death,” *Annals of Internal Medicine*, vol. 147, no. 8, pp. 578–581, 2007.

[123] R. A. Ajan and P. J. Grant, “The cardiovascular safety of rosiglitazone,” *Expert Opinion on Drug Safety*, vol. 7, no. 4, pp. 367–376, 2008.

[124] C. E. Murphy and P. T. Rodgers, “Effects of thiazolidinediones on bone loss and fracture,” *Annals of Pharmacotherapy*, vol. 41, no. 12, pp. 2014–2018, 2007.

[125] B. Seed, “PPARy and colorectal carcinoma: conflicts in a nuclear family,” *Nature Medicine*, vol. 4, no. 9, pp. 1004–1005, 1998.

[126] R. A. Gupta and R. N. Dubois, “Controversy: PPARy a target for treatment of colorectal cancer,” *American Journal of Physiology*, vol. 283, no. 2, pp. G266–G269, 2002.

[127] J. El-Hage, “Preclinical and clinical safety assessments for PPAR agonists,” 2004, http://www.fda.gov/cder/present/DIA2004/Elhage.ppt.

[128] A. Rubenstrunk, R. Hanf, D. W. Hum, J.-C. Fruchart, and B. Stael, “Safety issues and prospects for future generations of PPAR modulators,” *Biochimica et Biophysica Acta*, vol. 1771, no. 8, pp. 1065–1081, 2007.

[129] K. B. Michels, C. G. Solomon, F. B. Hu, et al., “Type 2 diabetes and subsequent incidence of breast cancer in the nurses' health study,” *Diabetes Care*, vol. 26, no. 6, pp. 1752–1758, 2003.

[130] E. Giovannucci, “Insulin, insulin-like growth factors and colon cancer: a review of the evidence,” *The Journal of Nutrition*, vol. 131, no. 11, pp. 3109S–3120S, 2001.

[131] J. A. Dormandy, B. Charbonnel, D. J. Eckland, et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROActive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial,” *The Lancet*, vol. 366, no. 9493, pp. 1279–1289, 2005.

[132] R. Govindarajan, L. Ratnasinghe, D. L. Simmons, et al., “Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes,” *Journal of Clinical Oncology*, vol. 25, no. 12, pp. 1476–1481, 2007.

[133] Y. Tsubouchi, H. Sano, Y. Kawahito, et al., “Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-y agonists through induction of apoptosis,” *Biochemical and Biophysical Research Communications*, vol. 270, no. 2, pp. 400–405, 2000.

[134] T.-H. Chang and E. Szabo, “Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor y in non-small cell lung cancer,” *Cancer Research*, vol. 60, no. 4, pp. 1129–1138, 2000.
[135] R. Govindarajan, E. R. Siegel, D. L. Simmons, and N. P. Lang, “Thiazolidinedione (TZD) exposure and risk of squamous cell carcinoma of head and neck (SCCHN),” *Journal of Clinical Oncology*, vol. 25, no. 18S, p. 1511, 2007.

[136] M. E. Ramos-Nino, C. D. MacLean, and B. Littenberg, "Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System," *BMC Medicine*, vol. 5, article 17, pp. 1–7, 2007.